- Clone
- 1A8 (See other available formats)
- Regulatory Status
- RUO
- Other Names
- Lymphocyte antigen 6 complex, locus G
- Isotype
- Rat IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Save |
---|---|---|---|
127627 | 125 µL | ¥37,620 | |
127628 | 50 µg | ¥51,730 |
Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Product DetailsProduct Details
- Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Ly-6G transfected EL-4J cell line.
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- Preparation
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
- Concentration
- µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
IHC-F - Verified - Recommended Usage
-
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet™.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents. - Excitation Laser
-
Violet Laser (405 nm)
- Application Notes
-
While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416.
Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662). -
Application References
(PubMed link indicates BioLegend citation) -
- Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
- Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
- Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
- Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
- Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
- Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
- Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
- Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
- Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
- Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
- Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
- Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
- Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
- Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
- Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
- Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
- Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
- McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
- Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
- Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
- Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
- Product Citations
- RRID
-
AB_10897944 (BioLegend Cat. No. 127627)
AB_2562567 (BioLegend Cat. No. 127628)
Antigen Details
- Structure
- A 21-35 kD GPI-anchorded membrane protein
- Distribution
-
Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
- Cell Type
- Granulocytes, Macrophages, Monocytes
- Biology Area
- Immunology, Innate Immunity
- Antigen References
-
Fleming TJ, et al. 1993. J. Immunol. 151:2399.
- Gene ID
- 546644 View all products for this Gene ID
- UniProt
- View information about Ly-6G on UniProt.org
Related Pages & Pathways
Pages
Related FAQs
- What is the F/P ratio range of our BV421™ format antibody reagents?
-
It is lot-specific. On average it ranges between 2-4.
Customers Also Purchased
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
Follow Us